It can, therefore, be suggested that direct agonism of the CB1 receptor (using CB1 receptor ligands) leads to cognitive dysfunction, while indirect modulation of the activity of this receptor (using FAAH or MAGL enzyme inhibitors) does not lead to cognitive impairment [11]. The gene discussed is MGLL; the disease is Cognitive impairment.